Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T16:35:51.910Z.
Calculation as of: 2026-10-06T16:35:51.910Z.
Quote observation: 2026-10-06T16:28:33.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d0d3cab615a00e4182867faf392a700f3c2ff11ca91232cb78ad2c83a49f3690
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Bone Biologics Corporation
Market Cap
$866810.00
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$880215.00
EV/Sales Ratio
N/A
TTM Avg
4140.29x
3Y Avg
121199.79x
5Y Avg
70235.45x
Market Cap
$885939.00
EV/Sales Ratio
N/A
TTM Avg
48327.79x
3Y Avg
43699.06x
5Y Avg
43699.06x
Market Cap
$851096.00
EV/Sales Ratio
N/A
TTM Avg
78.84x
3Y Avg
47.25x
5Y Avg
902.93x
Market Cap
$822391.00
EV/Sales Ratio
N/A
TTM Avg
2170.65x
3Y Avg
2189.01x
5Y Avg
2189.01x
Market Cap
$1.04M
EV/Sales Ratio
N/A
TTM Avg
26520.58x
3Y Avg
26520.58x
5Y Avg
26520.58x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bone Biologics Corporation (BBLG) | $866810.00 | N/A | N/A | N/A | N/A |
| Sunshine Biopharma, Inc. (SBFM)vs › | $880215.00 | N/A | 4140.29x | 121199.79x | 70235.45x |
| GlucoTrack, Inc. (GCTK)vs › | $885939.00 | N/A | 48327.79x | 43699.06x | 43699.06x |
| Decoy Therapeutics Inc. (DCOY)vs › | $851096.00 | N/A | 78.84x | 47.25x | 902.93x |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $822391.00 | N/A | 2170.65x | 2189.01x | 2189.01x |
| Ridgetech, Inc. (RDGT)vs › | $773249.00 | N/A | 0.20x | 0.19x | 0.16x |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.04M | N/A | 26520.58x | 26520.58x | 26520.58x |
| CDT Equity Inc. (CDT)vs › | $685948.00 | 0.67x | 1.27x | 1.27x | 1.27x |
| Clearmind Medicine Inc. (CMND)vs › | $1.06M | N/A | N/A | N/A | N/A |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.10M | N/A | N/A | N/A | N/A |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
